Annexin Pharmaceuticals (ANNX.ST) Stock Analysis & AI Equity Report
Annexin Pharmaceuticals (ANNX.ST) overview
Annexin Pharmaceuticals (ANNX.ST) stock analysis and AI equity research. For the latest completed financial year, 2025, Annexin Pharmaceuticals reported revenue of SEK 0m and operating profit of SEK -36.3m; the year-end share price was 19.80 SEK and market capitalisation was SEK 131m. Annexin Pharmaceuticals is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get Annexin Pharmaceuticals's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.
Key metrics & valuation multiples
Figures updated on 2026-07-27. Data will be refreshed during report generation.
About Annexin Pharmaceuticals
Annexin Pharmaceuticals AB (publ) is a clinical-stage biotechnology company focused on developing ANXV, a recombinant form of human Annexin A5. The company is advancing the program for diseases associated with vascular damage and inflammation, with current clinical work in ophthalmology and oncology. Its value drivers include product development, patent protection, and potential future licensing or commercialization.
Generate the Annexin Pharmaceuticals report
Annexin Pharmaceuticals is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.
Sources & methodology
Financial figures are sourced from Valuatum's financial model for Annexin Pharmaceuticals and represent the latest completed financial year (2025). See the methodology for the full Valuatum AI equity research framework.
Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.
Analyst reports on Annexin Pharmaceuticals
Each is this company's Valuatum report re-run with an analyst's own assumptions and published under their name. They are ordered by what other analysts said the work added over the engine's report — a score out of five from people who had to read it to give it.